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Summary The prognostic factors for response to chemotherapy and the prognostic impact of response status
on survival, relative to other prognostic variables, were evaluated among 53 responding (9 complete
responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung
(ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only
significant predictor of response was bidimensionally measurable disease parameter (P=0.02), followed by
brain metastases that were negatively correlated to response, although insignificantly (P=0.10). Univariate
landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for
responders compared with non-responders, but did not reach a significant level at any time (P values 0.78,
0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79
and 0.73. Muftivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact
on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact
of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results
achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the
cytostatic treatment currently available.
Chemotherapy has been widely employed in the treatment of
non-resectable adenocarcinoma of the lung (ACL), but
without substantial success. Only 20-40% of the patients
achieve an objective response with the best treatment
regimens and the majority of responses observed are only
partial (S0rensen et al., 1988a; S0rensen & Hansen, 1988). A
prolonged survival for patients on chemotherapy compared
with untreated patients has recently been documented in a
multicentre trial, showing that the administration of chemo-
therapy can improve, in a modest way, the overall survival
of treated patients with advanced non-small cell lung cancer
(P=0.02) (Rapp et al., 1988). The impact of response status
on survival, relative to other potential prognostic factors, is
of interest for a detailed characterisation of the prognosis in
patients treated with chemotherapy.
The comparison of survival distributions between
responding and non-responding patients presents difficulties
(Anderson et al., 1983). Comparing pretreatment variables
for frequencies of patients eventually achieving a response
during chemotherapy is hampered by different durations of
the periods 'at risk' for response for individual patients.
Patients with a long survival may be on study and have the
opportunity to respond for a longer time than patients who
die early. Thus, analyses which do not take this into account
may in part reflect prognostic factors for survival rather than
prognostic factors for response.
Another point is that a statistical procedure testing the
equality of survival distributions between the responder and
non-responder groups only demonstrates an association
between response and survival, not between cause and effect
(Weiss et al., 1983). This association may not be of any
relevance to the efficacy of treatment, but response may
simply serve as an indicator for patients with otherwise
positive prognostic features.
The response status at a given landmark time may thus be
considered a possible prognostic factor for the future
survival of patients, giving additional information about the
individual patient. Accordingly, the response status has been
discussed as a potential prognostic variable, e.g. in studies by
the Eastern Cooperative Oncology Group (Ruckdeschel et
al., 1985, 1986). The death rate for patients with metastatic
non-small cell lung cancer (NSCLC) who never responded to
chemotherapy was significantly higher than for patients who
did respond (P<0.001, Mantel-Byar test), but the level of
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significance for the individual histological types of NSCLC is
still unknown. Both response rate (Eagan et al., 1986) and
survival (Rapp et al., 1988, Eagan et al., 1986) may vary
among the histological types. Accordingly, to eliminate any
bias caused by varying proportions of squamous cell
carcinoma, adenocarcinoma and large cell carcinoma in the
studies, an analysis of the clinical impact of response could
be performed exclusively for one of the histological types or
the analysis could be stratified according to the histological
types. The former solution was chosen in the present study.
The side-effects of chemotherapy and the variability in
responsiveness to the same therapy makes it important for
investigators to identify predictors of response. Pretreatment
variables used for prognostic information regarding survival
may not necessarily be identical to the variables predicting
response, and the assessment of such variables should be
subjected to separate analyses.
The present study was thus restricted to inoperable
patients with ACL and performed to identify pretreatment
variables predicting response to chemotherapy. Another goal
was to examine the association between response status and
survival, thereby evaluating the prognostic impact of
response relative to other potential prognostic variables.
Materials and methods
Patients
The present series includes 259 consecutive patients with
inoperable ACL treated within a prospective randomised
chemotherapy trial from February 1981 to August 1985. The
treatment was either vindesine alone or a regimen of cyclo-
phosphamide, methotrexate and lomustine or a combination
of all four drugs. Details of the treatments and the treatment
results have previously been published (S0rensen et al.,
1987). All patients had a Karnofsky performance status of
50% or better, a maximum age of 70 years and none had
received prior chemotherapy or irradiation. Chest X-rays
were taken at least monthly. At progression of their disease,
the patients could receive palliative irradiation or
chemotherapy in phase I or phase II studies provided that
their performance status was acceptable, i.e. better than 4 on
the Zubrod scale (Zubrod et al., 1960).
Pretreatment histological or cytological materials from all
patients were evaluated according to the WHO classification
(WHO, 1981) by the pathologist at the respective hospitals.
Only patients satisfying the criteria for ACL were included.
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Subtyping of ACL was done retrospectively and blinded for
the clinical results by one pathologist. The subtyping was
based on histological material from 220 patients while
cytological material alone was available from 39 patients
(S0rensen et al., 1988b).
Routine pretreatment evaluation consisted of complete
history, including pulmonary and extrapulmonary symptoms
as well as weight loss during the preceding 6 months, general
physical examination with biopsy or needle aspiration from
suspected superficial foci, bone marrow biopsy from
posterior iliac crist and chest X-ray. In addition, bilateral
mammography and pelvic examination were performed in
females if the diagnosis of ACL was not based upon
cytological or histological bronchial material. Bone or liver
scans were not taken routinely. Brain scans were done in
symptomatic patients only.
Various biochemical tests were obtained before therapy,
including complete blood counts and plasma values of
prothrombin index, aspartate aminotransaminase (AST),
lactate dehydrogenase (LDH) and alkaline phosphatase.
Patients were characterised as having either limited or
extensive disease, the latter referring to spread outside the
lung and regional lymph nodes, including the ipsilateral and
contralateral supraclavicular nodes.
Patients with measurable (bidimensionally measurable)
and evaluable disease (unidimensionally measurable) were
included in the trial as were patients without a useful
objective parameter. However, only the patients in the two
former groups qualified for response and were included in
the present analysis. Response assessment was performed
according to WHO criteria (WHO, 1979). In case of
complete (CR) or partial remission (PR) the date of the first
Table I Pretreatment patients characteristics and histopathology
evaluated for prediction of response status among 157 patients alive
at 16 weeks
No. of patients alive
at 16 weeks (%)
Response No response
Variables (n =39) (n = 118)
Treatment
One drug (VDS)l 13 (27) 36 (73)
Three drugs (CTX+CCNU+MTX)a 10 (19) 42 (81)
Four drugs (VDS + CTX + CCNU + MTX)a 16 (29) 40 (71)
Histological subtyping
Acinar 20 (25) 60 (75)
Papillary 3 (21) 11 (79)
Bronchiolo-alveolar 2 (33) 4 (67)
Solid carcinoma 6 (30) 14 (70)
Differentiation
Well +moderate 8 (28) 21 (72)
Poorly 23 (25) 68 (75)
Performance status
Karnofsky 90-100% 16 (24) 52 (76)
70-80% 17 25) 50 (75)
50-60% 6 (27) 16 (73)
Sex
Male 19 (23) 65 (77)
Female 20 (27) 53 (73)
Non-radical resection
No 34 (24) 108 (76)
Yes 5 (33) 10 (66)
Age
<57 years 12 (17) 59 (83)
>57 years 27 (31) 59 (69)
Weight loss
0-5% 28 (27) 77 (73)
>5% 9(20) 37(80)
Pulmonary symptoms
No 8 (28) 21 (72)
Yes 31 (24) 96 (76)
Extrapulmonary symptoms
No 22 (26) 62 (74)
Yes 17 (24) 55 (76)
aVDS, vindesine; CTX, cyclophosphamide; CCNU, lomustine;
MTX, methotrexate.
observation of response was noted. All responses were
verified by two observers. Survival was recorded from the
day of randomisation to the day of death or the most recent
update (February 1987).
The proportion of responders according to the
pretreatment variables was compared using the x2 test
(Armitage, 1971).
Univariate landmark analyses
All patients responding before a given landmark time were
compared with all patients who had not yet responded. In
the analysis of the prognostic impact of response, it must be
taken into consideration that a patient showing the first sign
of response by day 28 (4 weeks) of study must survive at
least until day 56 (8 weeks) in order to qualify for a response
(WHO, 1979). Accordingly, the survival for patients
classified as having a response no later than at 4 weeks and
who were alive at 8 weeks was compared with the survival of
non-responding patients alive at 8 weeks using Kaplan-
Meier plots (Kaplan & Meier, 1958) and the log rank test
(Peto et al., 1977). Patients showing the first sign of response
after 4 weeks of study were classified as non-responders in
the present univariate landmark analysis of future survival
among patients alive at 8 weeks, whereas patients who died
before 8 weeks were not included in this particular analysis.
A similar procedure was followed for analyses of patients
responding at 8, 12 and 20 weeks and alive at 12, 16 and 24
weeks, respectively.
Table II Pretreatment disease parameters and disease spread evalu-
ated for prediction of response status among 157 patients alive at 16
weeks
No. of patients alive




Evaluable 11 (15) 63 (85)
Measurable 28 (34) 55 (66)
Chest X-ray
No complications 25 (26) 70 (74)
Complications 14 (23) 46 (77)
Lymph node metastases
No 11 (20) 45 (80)
Yes 27 (27) 72 (73)
Brain metastases
No 38 (27) 104 (73)
Yes 1 (7) 14(93)
Liver metastases (evidenced by
ultrasonic or scintigrafic scans)
No 39 (25) 115 (75)
Yes 0 (0) 3 (100)
Bone metastases (evidenced by
scintigrafic scans)
No 35 (26) 101 (74)
Yes 4 (19) 17 (81)
Bone marrow examination from
posterior iliac crist
Negative 20 (19) 84 (81)
Positive 3 (30) 7 (70)
Disease extent"
Limited 23 (29) 56 (71)
Extensive 16 (21) 62 (79)
Metastatic sites
above diaphragma
0-1 23 (22) 81 (78)
> 1 16 (30) 37 (70)
Metastatic sites
below diaphragma
0 34 (24) 105 (76)
>0 5 (28) 13 (72)
aMeasurable disease =bidimensionally measurable; evaluable
disease=unidimensionally measurable. bLimited disease=confined to
lung and regional lymph nodes including ipsilateral and contrelateral
supraclavicular nodes; extensive disease=spread beyond these sites.PROGNOSTIC IMPACT OF RESPONSE IN ACL 391
Multivariate regression analyses
Twenty-seven pretreatment variables (Tables I-III) were
chosen for analysis either because previous studies had
indicated a possible effect on prognosis or because such an
effect seemed likely. For each variable, the division was
chosen before the analysis without knowledge of the number
of responses in each groups. Thus, with respect to response
prediction, the level of significance was not influenced
artificially by these choices.
An analysis was performed, in which these variables were
tested for prediction of response among the patients
surviving 16 weeks using multiple logistic regression (Cox,
1970). Similarly, the pretreatment variables were included
together with response status in an analysis of future survival
among patients alive at 16 weeks using Cox's proportional
hazards model (Cox, 1972). This particular group of patients
was chosen for analysis in advance because a substantial part
of the responses had occurred at that time and the majority
of patients were still alive (Table IV).
The proportional-hazard assumption, which is a condition
for applying the Cox multivariate analysis on these data, was
checked by graphical and numerical methods (Anderson,
1982) and found not to be violated.
Results
A total of 259 patients were entered into the trial. Response
assessment was possible in 218 patients who had either
measurable (110 patients) or evaluable disease (108 patients),
and the following analysis is based on these patients. The
Table III Pretreatment laboratory values evaluated for prediction
of response status among 157 patients alive at 16 weeks
No. of patients alive




>7.5mM 28 (21) 103 (79)
<7.5mM 11 (42) 15 (58)
Platelets
400 x 109 1 22 (25) 65 (75)
>400 x 1091-P1 17 (24) 53 (76)
White blood cell count
<9 x 109 I-, 23 (28) 58 (72)
>9 x 1091-1 16 (22) 58 (78)
Prothrombin index
<0.70 3 (38) 5 (62)
>0.70 17 (20) 70 (80)
AST
K40UI 37 (25) 112 (75)
>40UP-' 2 (20) 8 (80)
Alkaline phosphatase
K275UP-1 25 (24) 81 (76)
>275UPl1 14 (27) 37 (73)
LDH
<450Ul-1 24 (26) 68 (74)
>450UI-1 10 (22) 36 (78)
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Figure 1 Comparison of survival among 39 responding
and 118 non-responding (--) patients alive at 16 weeks
(P=0.23).
disease parameters are listed in Table V. Fifty-three patients
achieved a complete (9 patients) or partial response (44
patients) (S0rensen et al., 1987). No attempt was made to
distinguish between the prognostic implications of these two
response types, but for the purpose of analysis patients were
categorised as either responders (CR or PR) or non-
responders. The responses to chemotherapy were in 50
patients documented by chest X-rays and in three patients
exclusively by superficial lymph nodes (Table V). Median
time to response (lasting a minimum of 4 weeks) was 10
weeks, while the median response duration was 15 weeks .
Prognostic factors for response (univariate x2 test and
multivariate logistic regression analysis)
Among the pretreatment variables listed in Tables I-III, only
two were associated with response in univariate analyses.
Evaluable disease parameter (P<0.01), and haemoglobin
level above 7.5mmoll-1 (P<0.025) predicted low response
rates. All variables were further evaluated in a multivariate
logistic regression analysis for independent prediction of
response among patients surviving 16 weeks. Only the
variable dividing disease parameter into measurable and
evaluable disease was of independent prognostic significance
for the attainment of response. The estimated probability for
response was 0.16 among patients having evaluable disease
and 0.33 among patients having measurable disease
(P=0.02).
A minor influence on response rate was noted for brain
metastases (P=0.10). Only one of 15 patients with brain
metastases at study entry and still alive at 16 weeks achieved
a response to chemotherapy. The probability of response was
0.37 in patients with measurable disease and no brain
metastases, decreasing to 0.16 in patients without brain
metastases and evaluable disease, and 0.086 and 0.029 for
patients with brain metastases and measurable or evaluable
disease, respectively. No other pretreatment variables were of
influence for response.
Table IV Univariate landmark analysis of patients alive at 8. 12, 16 and 24 weeks according to
response status
Death hazard
Survival responders ratio responders
Time on Total Response status vs. non-responders to non-responders
study no. (Univariate analysis, (95% confidence
(weeks) alive Response No response P values) intervals)
0 218
8 189 10 179 (0.78) 0.91 (0.48-1.73)
12 173 30 143 (0.57) 0.89 (0.60-1.33)
16 157 39 118 (0.23) 0.79 (0.54-1.16)
24 122 44 78 (0.12) 0.73 (0.49-1.09)
1, 1%
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Prognostic impact of response (univariate landmark analysis
and Cox's multivariate regression analysis)
Table IV shows the response status for patients alive at
different landmark times together with death hazard ratios
and the P-values from univariate survival comparison. The
median survivals for patients having a response at 8, 12, 16
and 24 weeks were 43 weeks, 43 weeks, 49 weeks and 48
weeks, while corresponding values for non-responders were 34
weeks, 36 weeks, 40 weeks and 49 weeks, respectively. The
comparison of survival curves for responders versus
nonresponders did not show significant differences at any
time.
The relative frequency of responding patients to the total
number of patients alive increased from 5.3% among those
alive at 8 weeks to 36.1% at 24 weeks on study. The
majority of responses (77%) occurred within the first 12
weeks, and all but one were noted before 20 weeks of
treatment. Forty-four of these 52 responding patients (85%)
were still alive at 24 weeks. There was no significant survival
advantage for responding patients in any of the four
landmark analyses.
The death hazard ratios for responding to non-responding
patients at these landmark times were 0.91 (95% confidence
intervals: 0.48-1.73), 0.89 (0.61-1.33), 0.79 (0.54-1.16), and
0.73 (0.49-1.09), respectively. Figure 1 shows the survival
curves according to response status for all patients alive at
16 weeks, who formed the basis of the multivariate analyses.
A multivariate regression analysis was performed including
response status among the 157 patients surviving 16 weeks
together with the pretreatment variables from Tables I-III.
Response status showed no impact on survival when
evaluated against the pretreatment variables (regression
coefficient =0.1268; standard error = 0.2253; P= 0.57). The
pretreatment variables describing performance status, non-
radical resection, presence of liver metastases and LDH
carried significant and independent information on survival
in the Cox analysis among the 130 patients alive at 16 weeks
for whom complete information was available on all these
variables (Table VI). No other pretreatment variables
showed any significant influence.
Discussion
Together with response duration and overall survival,
evaluation of response rates plays a key role in medical
oncology, especially in phase II trials but also in phase III
trials. The present state of chemotherapy for inoperable
ACL indicates that at the most one-third of the patients
included achieve a response to the regimens available today
and complete responses seldom occur (S0rensen et al., 1988a;
S0rensen & Hansen, 1988). Assessment of the influence of
various prognostic factors for response is therefore pertinent
when evaluating response data, in the stratification of
patients, and when selecting the inclusion criteria.
Univariate analysis of 27 variables for prediction of
response in this study increases the possibility of statistical
significance occurring by chance.. The finding of
haemoglobin >7.5mm as a predictor of low response rate




Location of patients (CR or PR)
parameters (n =218) (n =53)
Chest X-ray alone 174 37
Chest X-ray+palpable lymph node 34 11
Chest X-ray+other locations 6a 2
Palpable lymph node alone 3 3
Other locations alone lb 0
aCutaneous metastases, 5 patients; superficial sternal and cranial
tumour, 1 patient; bcutaneous metastases, 1 patient.
(P=0.025) may be a chance finding, and this variable is not
among the significant predictors in multivariate analysis.
In the present study, a multiple logistic regression analysis
was performed for patients alive at 16 weeks and classified
according to response status. Only the pretreatment variable
dividing disease parameter into measurable and evaluable
disease was associated with significant and independent
information. Ruckdeschel et al. (1985) observed a somewhat
higher overall response rate for patients with non-small cell
lung cancer having measurable disease as compared to non-
measurable disease in a multiple logistic regression analysis
(P=0.04). This observation, however, was not confirmed in
a later study by the same group of investigators
(Ruckdeschel et al., 1986). Eagan et al. (1979) observed no
differences in response rates between patients with
measurable or evaluable disease in a preceding univariate
analysis.
It is conceivable that the lower response rate for patients
with evaluable disease observed in the present study may not
be caused by biological differences. Rather, it reflects the
difficulties of quantitating response, as previously
emphasised by Warr et al. (1984), especially in lesions
not bidimensionally measurable. Obviously, response
assessment is more difficult in partial remission than in
complete remission. Unfortunately, the majority of responses
in this study, as in other trials with chemotherapy in
NSCLC, are only partial.
Other studies using multiple logistic regression analysis
found weight loss larger than 10kg during the preceding 3
months (Rapp et al., 1988) or Karnofsky performance status
and the presence of bone metastases (O'Connell et al., 1986)
to be of independent prognostic significance for the
attainment of response.
One method of analysing the results of treatment for non-
small cell lung cancer is to compare the survival for
responders and non-responders (Aisner & Hansen, 1981).
Unfortunately, such an analysis is associated with major
methodological and interpretational pitfalls. The frequently
used method of analysing survival by response, which
involves dividing patients into two groups according to
whether or not they ever achieve a response, is invalid
(Anderson et al., 1983). The method counts survival time
before response as time at risk of death for the responding
patient group, thereby underestimating the death rate for
responders and overestimating the death rate for non-
responders. As a result, neither the log rank test nor any
other test for statistical significance provides a valid
comparison of the risk of death in the two groups. Instead,
there are two other valid methods for testing the hypothesis
that responders have better survival than non-responders: the
Mantel-Byar approach (Mantel & Byar, 1974) and the
landmark method (Anderson et al., 1983). The latter method
is used in the present study.
A correlation between response and survival has
previously been reported in clinical trials of patients with
non-small cell lung cancer by both the Mantel-Byar method
(Ruckdeschel et al., 1985, 1986) and the landmark method
(Ruckdeschel et al., 1985). These two large studies included
432 and 486 NSCLC patients, respectively.
The present study evaluated the relationship between
Table VI Cox multivariate regression analysis of prognostic factors
for future survival among ACL patients alive after 16 weeks
on-study
Pretreatment Regression Standard
variable coefficient error P value
Performance status= 50-60% 1.2168 0.4378 0.0063
(0/1)a
Non-radical resection -0.8687 0.3440 0.0062
(0/1)a
Liver metastases 2.2827 0.7504 0.0089
(0/1)a
Ln(LDH) 0.7334 0.2770 0.0140
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response and survival solely in patients with ACL. No
significant prognostic impact was observed for response
status, although there was a trend towards longer survival
for responding patients, especially among those alive at 24
weeks (P=0.12). However, response status did not carry
prognostic information in multivariate analyses when
compared with the pretreatment variables (P=0.57). In
contrast, O'Connell et al. (1986) observed that response to
platinum-based chemotherapy was strongly associated with
survival among 352 patients with inoperable NSCLC of all
three major histological types. Other significant pretreatment
variables were performance status, LDH, sex and number of
extrathoracic metastases. Whether the difference in
prognostic impact of response status between the present
study and that of O'Connell et al. is due to the different
chemotherapy regimens employed, differences between the
histological tumour types included or stochastic variation
cannot be determined.
In the present study, patients with ACL responding to the
drugs lived only slightly longer than non-responding
patients, and response status was not a major predictor of
future survival. An explanation of this observation may be
that most of the responses, both in this study and in others
(S0rensen et al., 1988a; S0rensen & Hansen, 1988), were
partial. Some caution must be exerted when intepretating
these data. Firstly, a major disadvantage of the landmark
method is that the results depend on the selection of an
arbitrary landmark time, and conclusions of the analysis
may therefore differ according to the landmark chosen
(Anderson et al., 1983). However, none of the four landmark
analyses performed in this study showed any significant
differences in survival between responding and non-
responding patients.
Secondly, observer variation in response assessment may
account for some of the differences in response rates
observed in different studies (Warr et al., 1984) and may also
affect the significance of the correlation to survival. Efforts
were taken to diminish errors in response assessment, by
using two observers who strictly adhered to the WHO
guidelines for response assessment (WHO, 1979). This,
however, does not completely eliminate the possibility of
observer variations.
In conclusion, a response to the cytotoxic drugs used in
the present study was not a significant predictor of future
survival among patients with inoperable ACL. Patients
having measurable lesions had a greater likelihood of
responding than patients with evaluable lesions, and patients
with brain metastases seldomly responded. This may be of
importance for the patient selection in future studies and for
the interpretation of the results.
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